- Details
- At the 26th Annual Prostate Cancer Foundation Scientific Retreat 2019 (PCF 2019), Professor June Chan joins Charles Ryan to discuss her study "Eat, Move, Sleep," a digital cohort study that is focused on cancer survivorship aiming to collect data on diet, exercise, sleep, and other lifestyle practices in people with prostate, colorectal, and/or bladder cancer. This study is set to open in early 20...
|
- Details
- During the 2019 Advanced Prostate Cancer Consensus Conference (APCCC 2019), Susan Halabi joined Alicia Morgans to help interpret the various ongoing stage III clinical trials in prostate cancer. Dr. Halabi shares the top errors we can avoid in subgroup analyses. Biographies: Susan Halabi, Ph.D., Professor of Biostatistics and Bioinformatics, Duke Cancer Institute, Durham, North Carolina, United St...
|
- Details
- Cxbladder diagnostic tests combine genomic information from urinary mRNA with phenotypic information to either rule out low-risk individuals or identify patients at a high risk of urothelial carcinoma (UC). In this video presentation, Badrinath Konety overviews this study which aimed to evaluate the performance of Cxbladder and urine cytology and Cxbladder's adjudication of atypical cytology and e...
|
- Details
- Michael Morris, Professor of Medicine and GU Medical Oncologist, Memorial Sloan Kettering Cancer Center joins Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) to discuss the DORA trial. Michael Morris is The DORA trial principal investigator for this Prostate Cancer Clinical Trials Consortium (PCCTC) trial. The primary objective of this study is to compare...
|
- Details
- At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019), Oliver Sartor and Michael Morris join Charles to discuss lutetium in advanced prostate cancer and the VISION trial. Dr. Michael Morris serves on the scientific oversight committee of the trial, and Dr. Sartor is one of the co-PIs of this clinical trial. The VISION trial has the potential to change clinical practice in the...
|
- Details
- In this conversation, Alicia Morgans and Cora Sternberg, Medical Oncologist and Clinical Director of the Englander Institute for Precision Medicine, Weill Cornell Medicine in New York discuss the recently presented results from the CARD trial. The CARD Trial a phase 4 clinical trial compared cabazitaxel vs abiraterone or enzalutamide in patients who were previously treated with docetaxel and had p...
|
- Details
- Mary-Ellen Taplin, Professor of Medicine Harvard Medical School and a GU Medical Oncologist at the Dana-Farber Cancer Institute, joins Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) to speak about germline testing. They discuss what is required in implementing genetic testing into clinical practice and ways of disseminating the data to perform germline t...
|
- Details
- Stefano Fanti joins Phillip Koo at the 2019 European Associate of Urology to discuss the use of novel imaging methods in the prostate cancer space. Their discussion highlights the excitement and limitations around imaging including the methods of MRI and PET, and its impacts on patient care. Biographies: Stefano Fanti, Professor Department of Experimental, Diagnostic and Specialty Medicine - DIMES...
|
- Details
- Stefano Fanti reviews the consensus paper on nuclear imaging for prostate cancer which was recently published in Lancet Oncology in December 2018. PSMA PET should be offered early in biochemical recurrence as it is the most sensitive and the EAU has incorporated PSMA PET into their guidelines as well, recommending PSMA PET for PSA > 0.2. Stefano and Alicia discuss the various PSMA technologies and...
|
- Details
- Piet Ost shares details of his recent presentation focusing on biochemical recurrent prostate cancer, specifically in the recurrent setting, and answering the question such as should we be investing in this novel imaging for all patients or should we dial back a bit and only have that for selected patients? Who should get this imaging?. He expressed his intent to try to convince people to think be...
|
